Document Detail


Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance.
MedLine Citation:
PMID:  12472919     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Protease inhibitors used as therapy for HIV-1 infection have been associated with metabolic side-effects such as peripheral fat wasting, central adiposity, hyperlipidaemia and insulin resistance. This metabolic disorder is known as the lipodystrophy syndrome. This syndrome can be recognized by the early appearance of an increase in serum triglyceride, cholesterol and plasma-free fatty acid levels. Here, we describe an HIV-1 positive patient with the lipodystrophy syndrome in whom a decline in serum triglycerides was seen along with a significant improvement in glucose uptake following treatment with bezafibrate for 3 months. This improvement may be a consequence of the Randle effect, i.e. increased availability of plasma-free fatty acids is negatively correlated to glucose uptake. We also noted a significant improvement in endothelial-dependent flow-mediated dilatation after treatment with bezafibrate. This effect could result from the increased glucose uptake observed and a decrease in insulin resistance secondary to the lowered triglyceride levels by bezafibrate. We conclude that bezafibrate may be of clinical utility in the lipodystrophy syndrome, through its beneficial effects on insulin resistance, glucose uptake and endothelial dysfunction.
Authors:
T Nyström; G Bratt; A Sjöholm
Related Documents :
21700659 - A primary defect in glucose production alone cannot induce glucose intolerance without ...
21733949 - Factors associated with increased carotid intima-media thickness and being nondipper in...
16956689 - In addition to obesity and insulin resistance, microalbuminuria and diminished insulin ...
17362669 - Is pbef/visfatin/nampt an authentic adipokine relevant to the metabolic syndrome?
9705039 - Insulin resistance in essential hypertension is related to plasma renin activity.
18368459 - Remission of metabolic syndrome: a study of 140 patients six months after roux-en-y gas...
8335179 - Proinsulin levels in newborn siblings of type 1 (insulin-dependent) diabetic children a...
22226279 - What can we learn from patient-reported outcomes of insulin pen devices?
15827099 - Efficacy of octreotide-lar in dieting women with abdominal obesity and polycystic ovary...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of internal medicine     Volume:  252     ISSN:  0954-6820     ISO Abbreviation:  J. Intern. Med.     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-12-10     Completed Date:  2003-02-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8904841     Medline TA:  J Intern Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  570-4     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Karolinska Institutet, Stockholm South Hospital, Stockholm, Sweden. thomas.nystrom@sos.sll.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antilipemic Agents / therapeutic use*
Bezafibrate / therapeutic use*
Blood Glucose / metabolism*
Brachial Artery / drug effects
Endothelium, Vascular
HIV-Associated Lipodystrophy Syndrome / drug therapy*,  metabolism
Humans
Insulin Resistance / physiology*
Male
Vasodilation / drug effects
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Blood Glucose; 41859-67-0/Bezafibrate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Significant predictors of poor prognosis in women aged </=65 years hospitalized for an acute coronar...
Next Document:  Is primary angioplasty for some as good as primary angioplasty for all?